Distal Versus Total D2-Gastrectomy for Gastric Cancer: a Secondary Analysis of Surgical and Oncological Outcomes Including Quality of Life in the Multicenter Randomized LOGICA-Trial.

"Declarations DisclosuresRichard van Hillegersberg: consulting or advisory role: intuitive surgical, Medtronic. Jelle Ruurda: consulting or advisory role: intuitive surgical. Lodewijk Brosens: advisory role: Bristol Myers Squibb. Grard Nieuwenhuijzen: consulting or advisory role: Medtronic. The other authors have no disclosures. All authors declared no conflicts of interest. Disclosures Richard van Hillegersberg: consulting or advisory role: intuitive surgical, Medtronic. Jelle Ruurda: consulting or advisory role: intuitive surgical. Lodewijk Brosens: advisory role: Bristol Myers Squibb. Grard Nieuwenhuijzen: consulting or advisory role: Medtronic. The other authors have no disclosures. All authors declared no conflicts of interest."

"Funding The LOGICA-trial (NCT02248519) was funded by ZonMw (The Netherlands Organization for Health Research and Development), project number 837002502."

"This study is a secondary analysis in the prospective, multicenter LOGICA-trial to compare surgical and oncological outcomes including QoL after DG versus TG for resectable gastric adenocarcinoma (cT1–4aN0–3bM0) in 10 Dutch hospitals. The randomized controlled LOGICA-trial (NCT02248519) compared laparoscopic versus open D2-gastrectomy and showed no significant differences in surgical nor oncological outcomes including QoL. The study protocol and results were published previously.[,] The LOGICA-trial was approved by institutional review boards at each participating center, and written consent was obtained for all patients."